Thanks for your input. Feel free to chime in any time. It's good to have differing opinions contending so that we all can be as clear as possible in making our decisions. Good luck -Fritz
You say it lacks diversity but I love the diversity across companies in the customer base and the diversity across therapeutic areas served, and the diversity of markets, domestic and international, where the company's lead product can be used.
I think Helen's telling the truth when she talks about the high probability of success in phase 3 clinical trials when the subQ formulation is tried following success with the IV formulation.
Ease of administration and patient/clinician convenience are both power competitive advantages. Which reminds me, I'm not sure if Halo has many viable competitors outside of Big Pharma firms like Merck that choose to develop a SubQ formulation in-house.
However, like many on this board I am mystified as to why the stock hasn't done better. I chalk it up to the contagion effect: all of biotech is out of favor among investors right now, not just Halo. (The image below illustrates my point, it shows the XBI (broad biotech industry) ETF price for the past 5 years). So for this reason I think the timing of the share buyback makes a great deal of sense: Helen and her team think the stock is a great value at current prices, and they're putting their money where their mouth is.
News 
Market Data 
Discover 
